Emergence of resistance to fluoroquinolones and third-generation cephalosporins in Salmonella Typhi in Lahore, Pakistan by Rasheed, Farhan et al.
microorganisms
Brief Report
Emergence of Resistance to Fluoroquinolones and
Third-Generation Cephalosporins in Salmonella
Typhi in Lahore, Pakistan
Farhan Rasheed 1,* , Muhammad Saeed 2, Nabil-Fareed Alikhan 3, David Baker 3,
Mohsin Khurshid 2 , Emma V. Ainsworth 3 , A. Keith Turner 3, Ambereen Anwar Imran 1,
Muhammad Hidayat Rasool 2, Muhammad Saqalein 2, Muhammad Atif Nisar 2,
Muhammad Fayyaz ur Rehman 4 , John Wain 3,5, Muhammad Yasir 3,*, Gemma C. Langridge 3
and Aamer Ikram 6
1 Allama Iqbal Medical College & Jinnah Hospital (AIMC&JHL), Lahore 54000, Pakistan;
ambereen@outlook.com
2 Department of Microbiology, Government College University, Faisalabad 38000, Pakistan;
mian.muhsaeed@gmail.com (M.S.); mohsinkhurshid@gcuf.edu.pk (M.K.);
drmhrasool@gcuf.edu.pk (M.H.R.); drsaqalein@gcuf.edu.pk (M.S.); matifnisar@gcuf.edu.pk (M.A.N.)
3 Quadram Institute Bioscience, Norwich Research Park, Norwich NR4 7UQ, UK;
nabil-fareed.alikhan@quadram.ac.uk (N.-F.A.); david.baker@quadram.ac.uk (D.B.);
emma.ainsworth@quadram.ac.uk (E.V.A.); keith.turner@quadram.ac.uk (A.K.T.);
john.wain@quadram.ac.uk (J.W.); gemma.langridge@quadram.ac.uk (G.C.L.)
4 Department of Chemistry, University of Sargodha, Sargodha 40100, Pakistan; fayyaz9@gmail.com
5 Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich NR4 7TJ, UK
6 National Institute of Health, Islamabad 45710, Pakistan; maahin1@yahoo.com
* Correspondence: dr.farhanrasheed@gmail.com (F.R.); muhammad.yasir@quadram.ac.uk (M.Y.)
Received: 23 July 2020; Accepted: 28 August 2020; Published: 1 September 2020


Abstract: Extensively drug-resistant (XDR) Salmonella Typhi has been reported in Sindh province of
Pakistan since 2016. The potential for further spread is of serious concern as remaining treatment
options are severely limited. We report the phenotypic and genotypic characterization of 27 XDR
S. Typhi isolated from patients attending Jinnah Hospital, Lahore, Pakistan. Isolates were identified
by biochemical profiling; antimicrobial susceptibility was determined by a modified Kirby–Bauer
method. These findings were confirmed using Illumina whole genome nucleotide sequence data.
All sequences were compared to the outbreak strain from Southern Pakistan and typed using the
S. Typhi genotyping scheme. All isolates were confirmed by a sequence analysis to harbor an IncY
plasmid and the CTX-M-15 ceftriaxone resistance determinant. All isolates were of the same genotypic
background as the outbreak strain from Sindh province. We report the first emergence of XDR
S. Typhi in Punjab province of Pakistan confirmed by whole genome sequencing.
Keywords: Salmonella Typhi; typhoid fever; XDR; cephalosporin resistance; Lahore
1. Introduction
Typhoid fever, caused by Salmonella enterica, serotype Typhi (Salmonella Typhi) is a global health
concern. The burden of typhoid has been estimated at 13.5 million cases resulting in 135,000 deaths
annually, with a global incidence of 2.14 in 1000 [1,2]. In Pakistan, the precise burden is not known
but active surveillance studies in Karachi report 4.7 cases per 1000 per year. Travel-associated
typhoid fever is also of concern in high income countries with more than 150 cases of typhoid
fever annually in England and Wales since 2008 (Public Health England, 2018); most of these cases
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have a history of travel to South Asia. The treatment of typhoid was changed by the emergence of
multidrug resistance (MDR) in Salmonella Typhi, which rendered first line antibiotics (amoxycillin,
co-trimoxazole, and chloramphenicol) and fluoroquinolones ineffective [3]. The treatment of choice
became a third-generation cephalosporin, most commonly ceftriaxone [4]. In 2016, there was a report
from Karachi (Sindh province) of the emergence of extensively drug resistant (XDR) S. Typhi [5].
The S. Typhi strains described as XDR are MDR strains with additional fluoroquinolone and ceftriaxone
resistance, leaving azithromycin, piperacillin-tazobactam, or carbapenem as the treatment options [5].
While a report of fluoroquinolone or ceftriaxone resistance in the Enterobacteriaceae is not uncommon
in Pakistan, the isolation of S. Typhi harboring resistance to these antibiotics is much more unusual.
Since the first outbreak in Sindh, more than 17,000 XDR S. Typhi cases have been reported from
this province according to National Institute of Health, Pakistan [6]. Prevalence data for XDR S. Typhi is
not yet officially available outside Sindh province but there are case reports across the country [7,8],
from elsewhere in the region [9] and it is being further transmitted by travelers [10]. In the current
SARS-CoV-2 pandemic, a large number of typhoid fever cases have arisen with similar clinical fever
symptoms to COVID-19; more than 20,000 typhoid cases were reported in June 2020 in Pakistan [11].
Whole genome sequencing (WGS) has been used in the past to understand the evolution of
antibiotic resistance mechanisms and to track bacterial and viral pathogen spread [12,13]. WGS of
individual cases of XDR S. Typhi from Taiwan, Canada and Denmark have shown a close relationship
(100% nucleotide match) to the nearest sequenced XDR isolate from Pakistan [14–16]. This highlights
the international impact of this ongoing outbreak and that any SNPs found between isolates of S. Typhi
during an outbreak suggest prolonged transmission. This is the first study to use WGS for XDR S. Typhi
found in Pakistan outside of Sindh province, and was prompted by the blood culture isolation of XDR
S. Typhi from patients under investigation at Jinnah Hospital, Lahore. This raised the possibility that
the Sindh province strain was circulating in Lahore, leading us to sequence 27 XDR S. Typhi isolates
obtained in under 4 months in 2019 and compare SNPs in their whole genome sequences with those
from Sindh.
2. Materials and Methods
This study was carried out at the Department of Pathology, Jinnah Hospital, Lahore, Pakistan and
Quadram Institute Bioscience, Norwich, United Kingdom.
2.1. Isolation and Identification of Isolates
Blood cultures were collected, following normal diagnostic protocols, from patients with fever
admitted to the Jinnah Hospital Lahore, Pakistan. A Gram stain was performed directly from blood
culture broth; the broth was inoculated on blood agar and MacConkey agar. Bacterial colonies were
identified biochemically using API 10 or API 20E (BioMérieux, Marcy l’Etoile, France). Isolates were
confirmed as Salmonella Typhi by serological reactions to O, H, and Vi antigens (Pro-Lab Diagnostics,
Ontario, Canada). Antibiotic susceptibility testing was performed using a modified Kirby–Bauer
method according to Clinical Laboratory Standard Institute (CLSI) 2019 guidelines. Twenty-seven
XDR S. Typhi isolates were collected between January 2019 and April 2019 and archived at −80 ◦C.
The isolates were recultured on blood agar and DNA was extracted for sequencing from single colonies.
Not all of the isolates seen were XDR but as blood cultures were from patients who presented themselves
to health care services the data is not representative of the proportion of different strains circulating.
2.2. DNA Extraction
DNA extraction of S. Typhi isolates was carried out using a modified protocol of the PuriSpin
Fire Monkey kit (RevoluGen, Hadfield, UK). In brief, 1 mL overnight S. Typhi culture was harvested
and cells were resuspended in 100 µL of lysozyme (3 mg/mL), 1.2 % Triton X-100, and incubated at
37 ◦C, 180 rpm for 10 min. Of lysis solution 300 µL and 20 µL of proteinase K (20 mg/mL, Qiagen,
Manchester, UK) was added to the partly lysed cells and incubated at 56 ◦C for 20 min. After lysis,
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10 µL of RNase A (20 µg/µL, Sigma) was added to the suspension and incubated for a further 10 min
at 37 ◦C. Binding solution 350 µL and isopropanol (75%) 400 µL were added to the lysed cells and
the lysed cells were transferred to the spin column. Bound DNA was washed as per manufacturer’s
instructions and eluted in 2 × 100 µL of elution buffer. DNA was shipped to Quadram Institute
Bioscience, Norwich, UK and concentrations were determined using the Qubit dsDNA broad range
assay kit (Thermo Fisher, Loughborough, UK) on a Qubit 3.0 Fluorometer (Thermo Fisher).
2.3. Whole Genome Nucleotide Sequencing
Genomic DNA concentrations were adjusted to 0.5 ng/µL with nuclease-free water for sequencing.
A tagmentation mix of 3 µL was mixed with 2 µL of genomic DNA (0.5 ng/µL) and incubated at 55 ◦C
for 10 min in a PCR block. Kapa2G PCR master mix was added 11 µL to each well sample in a 96-well
plate alongside 2 µL of each of P7 and P5 of Nextera XT Index Kit v2 index primers (Illumina). The PCR
was carried out following standard Illumina guidelines. The DNA fragment libraries were quantified
using the Quant-iT dsDNA high sensitivity assay kit (Thermo Fisher) and pooled. The final pool was
double-SPRI size selected between 0.5 and 0.7 × bead volumes using KAPA Pure Beads (Roche) and
the pool was run at a final concentration of 1.8 pM on an Illumina Nextseq 500 instrument using a Mid
Output Flowcell (NSQ® 500 Mid Output KT v2 (300 CYS), Illumina). Data was uploaded to Basespace
(www.basespace.illumina.com) where the raw data was converted to 8 FASTQ files for each sample.
2.4. Genome Assembly and Annotation
Genome nucleotide sequences of all strains were determined using 150 bp paired-end sequencing
on the Illumina Nextseq 500 platform. All raw sequence data have been deposited in the NCBI Sequence
Read Archive (SRA) under BioProject accession PRJNA602421. Sequenced reads were screened using
Centrifuge v1.0.4 to confirm the species of each sample as Salmonella enterica [17]. De novo assembly of
individual genomes was carried out using Shovill v1.0.0 (https://github.com/tseemann/shovill, accessed
on 1 November 2019), which internally corrected sequencing errors, performed genome assembly using
SPAdes [18], and removed erroneous contigs. Assembly quality was assessed via QUAST v5.0.2 [19,20].
Draft genomes were annotated using Prokka v1.14 [21].
2.5. Genotyping and Antimicrobial Gene Prediction
In silico multilocus sequence typing was predicted using “MLST” v2.17.5 (https://github.com/
tseemann/mlst, accessed on 1 November 2019) using the Salmonella MLST database hosted by
EnteroBase [22]. To calculate the genotype using the Genotyphi scheme [23], draft genomes were
aligned using Parsnp v1.2 [13] to the S. Typhi CT18 reference genome (accession no. AL513382.1) and
resulting variant calls (vcf) were run through Genotyphi (commit version fd1d58b), as described on
the GitHub repository. Antimicrobial resistance genes were detected using ARIBA v2.14 [24] with
default parameters.
2.6. Phylogenetic Analysis
Ninety-two additional S. Typhi genomes were included to provide context to the 27 from this
study [5]. The outgroup and reference genome (ERL12148, accession no. LT883153.1) was selected
using the following criteria; the strain was closely related (i.e., S. Typhi haplotype H58) and the
strain was not associated with the 2016 outbreak. Single nucleotide polymorphisms (SNPs) were
identified against the reference using Snippy v4.2.1 (https://github.com/tseemann/snippy, accessed
on 1 November 2019) and visually inspected in Artemis [25]. Gubbins v2.3.1 [26] was used to define
non-recombinant SNPs, which were used with RaxML [27] to construct the final phylogeny. A reference
IncY plasmid (Pak60006-2016) [5] was used with Blast Ring Image Generator (BRIG) [28] to identify
nucleotide identity between the reference genome and strains genome sequenced as part of this study.
Microorganisms 2020, 8, 1336 4 of 9
2.7. Role of the Funding Source
The funders had no role in study design, in the collection, analysis and interpretation of data,
in the writing of the report or the decision to submit this paper for publication.
2.8. Ethics Statement
Ethical approval for this study was obtained from the ethical review board of Allama Iqbal Medical
College/Jinnah Hospital, Lahore at the 47th meeting held on 13 March 2019. All patient data was
anonymized to remove any identifying information.
3. Results
3.1. Phenotypic Findings
Although strict surveillance data is not available for typhoid fever in Lahore, a 12-fold increase
in isolation rate was observed at Jinnah Hospital over the 12-month period July 2018 to June 2019
(number of cases = 370) relative to the previous 12 months (n < 30). Twenty-seven isolates of
S. Typhi were isolated from the blood of consecutive patients between 14th January and 1st April 2019.
Fourteen isolates were from males and thirteen from females. The age range varied from 15 months to
28 years, with 11 of the isolates from under-fives, 13 from 5–16 years old, and 3 from >16 years old
(Table S1). This was a typical sample of patients presenting to Jinnah Hospital with suspected typhoid
fever. All of the isolates were phenotypically and biochemically identified as S. Typhi and serologically
confirmed as positive to O, Vi, and H antibodies. Antibiotic susceptibility testing showed that these
isolates were susceptible only to azithromycin, carbapenems, and piperacillin-tazobactam (Table S2).
All were resistant to the standard treatment for typhoid fever including ceftriaxone. For all patients,
treatment was started with intravenous meropenem followed by azithromycin. There was no mortality
reported due to XDR S. Typhi.
3.2. Genotypic Analysis
We compared our recent Lahore isolates to 100 S. Typhi genomes from Southern Pakistan and
generated a maximum-likelihood phylogenetic tree from 68 filtered and neutral SNPs (Figure 1). All the
XDR isolates differed by six SNPs from the MDR S. Typhi clade, the same level of variation as seen
during the 2016 outbreak. Our Lahore isolates also intermingled with those from the 2016 outbreak,
indicating few, if any, SNP differences between these strains. It is plausible therefore that all the XDR
isolates originated from a single strain that acquired the XDR phenotype. Within the XDR clade, the
Lahore isolates formed two clusters on the tree, one consisting of isolates XDR1, 21, 5, 28, and 27,
and the other of XDR24, 4, 17, 6, 13, 10, 23, 19, 30, 26, 25, 15, 22, 35, 31, and 2, suggesting probable
epidemiological linkage.
Analysis of all 27 draft genome sequences from Lahore indicated the presence of both an IncY
plasmid and the CTX-M-15 determinant associated with ceftriaxone resistance. The CTX-M-15
resistance determinant was located on an IncY plasmid in the Southern Pakistan outbreak strains; our
BRIG analysis suggested that this was also the case for the Lahore isolates (Figure 2).
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4. Discussion
Here we reported S. Typhi resistant to amoxycillin, co-trimoxazole, chloramphenicol, ciprofloxacin,
and ceftriaxone from Lahore, Pakistan. Our phenotypic and genotypic analysis shows that the S. Typhi
XDR isolates were indistinguishable from the outbreak strain described in Southern Pakistan, indicating
that the cases in Lahore are part of the same outbreak. Whole genome nucleotide sequences revealed
that all isolates were sequence type (ST)1 and identified as 4.3.1.1.P1 under the Genotyphi scheme,
the same as the strains from the 2016 outbreak reported in Sindh province [5,23]. We have investigated
a single tertiary health care facility in Lahore but alongside other reports, we believe it is spreading
locally [29]. The isolates from Jinnah Hospital are closely related but several of them harbor SNP
differences. Since S. Typhi is a clonal pathogen the presence of these SNPs suggests that either the
XDR strain is not a recent introduction to the area or that it has been imported several times [30].
The emergence of XDR S. Typhi in Lahore is likely the result of regular travel between Sindh, Karachi,
and Lahore encouraging national transmission, followed by the use of inactive antibiotics allowing
local transmission.
The increased level of S. Typhi isolation from blood culture is of serious public health concern.
Treatment of XDR S. Typhi is one of the growing challenges for infectious disease physicians in Lahore
and more widely in Pakistan. Treatment is a challenge because a typical typhoid patient is from a
poor socioeconomic background and the treatment of XDR is expensive. In Pakistan many adult
patients present to their GP or pharmacist and are treated empirically whereas children are more often
brought to the hospital [31]. The only treatment options that remain in this situation are azithromycin,
meropenem, and piperacillin/tazobactam. The treatment strategy for XDR typhoid is intravenous
meropenem for seven days, which costs 260 USD followed up by oral azithromycin; this is being used
in Pakistan as well as in internationally exported cases [16] but many patients skip treatment and return
later with complications (Asst. Prof. Fahad Aman Khan, personal communication). Carbapenems
are a potent class of antibiotics and an effective treatment for typhoid fever but the presence of
carbapenemase-producing Enterobacteriaceae is a critical threat [16,32]. This leaves many patients with
azithromycin as their only viable option (Asst. Prof. Fahad Aman Khan, personal communication) [33].
Furthermore, of the remaining treatment options for XDR S. Typhi, only azithromycin is
administered orally but the present danger is that mass administration of azithromycin for typhoid in
addition to prophylactic use in COVID-19 management may accelerate the emergence and spread of
azithromycin resistant XDR S. Typhi strains [34]. Resistance has already been reported in typhoidal
Salmonella, conferred by single nucleotide changes in the acrB efflux system, from Bangladesh [35]
and Pakistan [36], and the macrolide resistance genes mphA, mphB, and mefB have been reported as
conferring resistance in non-typhoidal Salmonella [37]. It is likely only a matter of time before one of
these mechanisms emerges in the XDR background, rendering carbapenems the only, more expensive,
treatment option. It is also of note that while azithromycin remains a viable treatment in susceptible
XDR isolates, it has been contraindicated for patients on arrhythmic, antipsychotics, and citalopram
medications leading to an increased risk of cardiovascular-related mortality [38].
In conclusion, the risk of single point mutations conferring resistance to azithromycin and of
the horizontal transmission of carbapenemase-mediated resistance makes the ongoing threat of XDR
typhoid fever very real in Pakistan and internationally. One significant advancement towards treatment
of typhoid in Pakistan is a program under development to provide the newly developed typhoid vaccine,
Typbar-TCV, to more than 1 million children (6 month to 10 years of age) across infected areas [39].
This will help reduce the prevalence of typhoid but the efficacy of this vaccine against continuously
emerging XDR typhoid will require evaluation for the next few years. Both epidemiological studies and
functional genomics are urgently needed to inform local, national, and international control measures
and future public health strategies.
Supplementary Materials: The following are available online at http://www.mdpi.com/2076-2607/8/9/1336/s1,
Table S1: Anonymised patient data. Table S2: Antimicrobial susceptibility testing results.
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